Sight Sciences downgraded by Lake Street with a new price target
$SGHT
Medical/Dental Instruments
Health Care
Lake Street downgraded Sight Sciences from Buy to Hold and set a new price target of $5.00 from $10.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/6/2024 | $5.50 | Buy | UBS |
| 11/4/2024 | $10.00 → $5.00 | Buy → Hold | Lake Street |
| 8/21/2024 | $10.00 | Buy | Lake Street |
| 9/12/2023 | $10.00 → $4.50 | Neutral → Underperform | BofA Securities |
| 9/12/2023 | $15.00 → $5.50 | Overweight → Neutral | Piper Sandler |
| 9/12/2023 | Outperform → Mkt Perform | William Blair | |
| 8/24/2023 | $12.00 → $8.40 | Overweight → Equal-Weight | Morgan Stanley |
| 7/10/2023 | $15.00 → $9.00 | Buy → Neutral | Citigroup |
MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con
MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023. "We are very excited to have Matt join Sight Sciences as we scale our Surgical Glaucoma and Dry Eye businesses. Matt is a highly talented medtech business leader with a track record of success in transforming treatment paradigms with disruptive new technology, and predictably scaling in a public high-growth
4 - Sight Sciences, Inc. (0001531177) (Issuer)
3 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
UBS initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $5.50
Lake Street downgraded Sight Sciences from Buy to Hold and set a new price target of $5.00 from $10.00 previously
Lake Street initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $10.00
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025. Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's
MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at
MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the fourth quarter and full year ended December 31, 2024 and initiated financial guidance for full year 2025. Recent Financial Highlights Generated fourth quarter 2024 total revenue of $19.1 million, an increase of 2% compared to the same period in the prior year, and full year 2024 total revenue of $79.9 million, a decrease of 1% compared to full year 2023.Achieved total gross marg
10-Q - Sight Sciences, Inc. (0001531177) (Filer)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
DEFA14A - Sight Sciences, Inc. (0001531177) (Filer)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G - Sight Sciences, Inc. (0001531177) (Subject)
MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum. Sight Sciences' management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the Investors section of the Company's website at https://investors.sightsciences.com/. About Sight Sciences Sight Sciences is an eyecar
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025. Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's
MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at